UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 129

Sortiert nach

Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes

Diabetes care, 2013-12, Vol.36 (12), p.3860-3862

2013

Volltextzugriff (PDF)

Insulin is Required for Prandial Ghrelin Suppression in Humans

Diabetes (New York, N.Y.), 2003-12, Vol.52 (12), p.2923-2927

2003

Volltextzugriff (PDF)

Validation of a Counseling Strategy to Promote the Adoption and the Maintenance of Physical Activity by Type 2 Diabetic Subjects

Diabetes care, 2003-02, Vol.26 (2), p.404-408

2003

Volltextzugriff (PDF)

Ghrelin Is Not Necessary for Adequate Hormonal Counterregulation of Insulin-Induced Hypoglycemia

Diabetes (New York, N.Y.), 2002-10, Vol.51 (10), p.2911-2914

2002

Volltextzugriff (PDF)

Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure

The journal of clinical endocrinology and metabolism, 2004-05, Vol.89 (5), p.2136-2141

2004

Volltextzugriff (PDF)

Circulating Ghrelin Concentrations in the Polycystic Ovary Syndrome

The journal of clinical endocrinology and metabolism, 2003-02, Vol.88 (2), p.942-945

2003

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Diabetes care, 2019-01, Vol.42 (1), p.85-92

2019

Volltextzugriff (PDF)

The physiological basis of insulin therapy in people with diabetes mellitus

Diabetes research and clinical practice, 2021-05, Vol.175, p.108839-108839, Article 108839

2021

Volltextzugriff (PDF)

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136

Diabetes care, 2021-03, Vol.44 (3), p.e59-e60

2021

Volltextzugriff (PDF)

Portal Vein Glucose Sensors Do Not Play a Major Role in Modulating Physiological Responses to Insulin-Induced Hypoglycemia in Humans

Diabetes (New York, N.Y.), 2009-01, Vol.58 (1), p.194-202

2009

Volltextzugriff (PDF)

Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage

Diabetes (New York, N.Y.), 2023-10, Vol.72 (10), p.1364-1373

2023

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Diabetes care, 2015-12, Vol.38 (12), p.2204-2210

2015

Volltextzugriff (PDF)

1088-P: A PK/PD and Metabolic Head-to-Head Comparison of Clinical Doses of Insulin Glargine U300 and Degludec in Type 1 Diabetes

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Liver protein synthesis in physiology and in disease states

Current opinion in clinical nutrition and metabolic care, 2002-01, Vol.5 (1), p.47-50

2002

Volltextzugriff (PDF)

The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?

Diabetes research and clinical practice, 2023-09, Vol.203, p.110828-110828, Article 110828

2023

Volltextzugriff (PDF)

One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs

Metabolism, clinical and experimental, 2022-01, Vol.126, p.154935-154935, Article 154935

2022

Volltextzugriff (PDF)

Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients

Kidney international, 2001-07, Vol.60 (1), p.235-242

2001

Volltextzugriff (PDF)

Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology

Current diabetes reports, 2018-10, Vol.18 (10), p.83-10, Article 83

2018

Volltextzugriff (PDF)

Lower Pharmacokinetic and Pharmacodynamic Within-Day Variability of Individual Clinical Doses of Insulin Glargine 300 U/ml vs. Glargine 100 U/ml in T1DM

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations

Nutrition, metabolism, and cardiovascular diseases, 2005-12, Vol.15 (6), p.410-417

2005

Volltextzugriff (PDF)

895-P: Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Diabetes care, 2015-12, Vol.38 (12), p.2237-2240

2015

Volltextzugriff (PDF)

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial

The Lancet (British edition), 2014-10, Vol.384 (9950), p.1265-1272

2014

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL -1 and Insulin Degludec 100 units · mL -1 in Type 1 Diabetes

Diabetes care, 2021-01, Vol.44 (1), p.125-132

2021

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes

Diabetes care, 2015-03, Vol.38 (3), p.503-512

2015

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(120)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(83)
Humans
(71)
Female
(51)
Male
(49)
Adult
(37)
Endocrinology & Metabolism
(33)
Biological And Medical Sciences
(29)
Medical Sciences
(25)
Middle Aged
(25)
Diabetes
(22)
Insulin
(20)
Blood Glucose - Metabolism
(15)
Cystic Fibrosis
(15)
Aged
(13)
Endocrinopathies
(13)
Adolescent
(12)
Diabetes. Impaired Glucose Tolerance
(11)
Endocrine Pancreas. Apud Cells
(11)
Glucose
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes

Insulin is Required for Prandial Ghrelin Suppression in Humans

Validation of a Counseling Strategy to Promote the Adoption and the Maintenance of Physical Activity by Type 2 Diabetic Subjects

Ghrelin Is Not Necessary for Adequate Hormonal Counterregulation of Insulin-Induced Hypoglycemia

Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure

Circulating Ghrelin Concentrations in the Polycystic Ovary Syndrome

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

The physiological basis of insulin therapy in people with diabetes mellitus

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136

Portal Vein Glucose Sensors Do Not Play a Major Role in Modulating Physiological Responses to Insulin-Induced Hypoglycemia in Humans

Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

1088-P: A PK/PD and Metabolic Head-to-Head Comparison of Clinical Doses of Insulin Glargine U300 and Degludec in Type 1 Diabetes

Liver protein synthesis in physiology and in disease states

The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?

One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs

Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients

Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology

Lower Pharmacokinetic and Pharmacodynamic Within-Day Variability of Individual Clinical Doses of Insulin Glargine 300 U/ml vs. Glargine 100 U/ml in T1DM

Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations

895-P: Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial

Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL -1 and Insulin Degludec 100 units · mL -1 in Type 1 Diabetes

Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes

Suchergebnisse filtern